Skip to main
ELTX

ELTX Stock Forecast & Price Target

ELTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Elicio Therapeutics is actively working on developing a promising immunotherapy vaccine, ELI-002, for KRAS-mutated cancers, particularly for patients with advanced stages of the disease. The company's focus on targeted delivery through their proprietary AMP technology and the use of a global Phase 3 trial to compare ELI-002 to other treatments demonstrates their commitment to advancing cancer treatment. Additionally, the expertise of the lead researcher in immunotherapy is a positive sign for the potential success of the vaccine.

Bears say

Elicio Therapeutics is a clinical-stage biotechnology company with a promising immunotherapy platform, but challenges lie ahead. While their 7P phase 1a trial showed a significant dose-response relationship with strong T cell responses and biomarker clearance in some patients, the sample size was small and the 7P trial was still maturing at the data cutoff. Additionally, the company faces regulatory and financial risks, as success in phase 2 testing may not guarantee regulatory approval and the company may need to raise additional capital to continue development.

ELTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elicio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elicio Therapeutics Inc (ELTX) Forecast

Analysts have given ELTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELTX has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elicio Therapeutics Inc (ELTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.